Artificial intelligence is reshaping how topical and transdermal drugs are discovered, formulated, tested, and monitored. What began as isolated experiments in computational chemistry has expanded into a coordinated effort across pharmaceutical companies, CDMOs, dermatology clinics, cosmetics firms, and regulators — all applying AI to solve one of medicine's oldest challenges: getting a drug through the skin effectively and safely. The market spans a wide value chain, from early-stage molecule design through post-market surveillance, and encompasses applications as varied as AI-optimized nanocarriers and deep learning-powered dermatology diagnostics.
This article traces how that transformation unfolded — from the first regulatory recognition of AI in pharmaceutical applications through the multi-billion-dollar deals and platform launches defining the field as of 2026.
2016–2023: Regulatory Recognition and the Groundwork Years
The story of AI in topical drug delivery begins with a regulatory signal. Between 2016 and 2023, the U.S. FDA reviewed more than 500 medication applications incorporating AI components. That figure marks something important: AI moved from research curiosity to a tool that pharmaceutical developers were actively deploying in submissions to the world's most influential drug regulator.
During this period, the underlying technology — machine learning, deep learning, generative models — was maturing rapidly. In pharmaceutical development, early adopters began applying these tools to problems that had long resisted conventional approaches. Topical drug delivery presented a particular opportunity. The stratum corneum is an extraordinarily effective barrier, and predicting how a drug molecule will cross it has historically required expensive, time-consuming laboratory work. AI offered a path to doing some of that computationally, using existing experimental data to train models that could screen candidates before a single laboratory experiment was run.
The broader investment environment was also building. Between 2012 and 2025, AI companies specializing in IT infrastructure and hosting attracted $256.1 billion in cumulative investment. The computational infrastructure that would later power drug-skin interaction simulations and formulation optimization tools was being funded throughout this decade, even if pharmaceutical applications were not yet fully realized.
2024: A Pivotal Year of Consolidation, Regulation, and Regional Expansion
If the preceding years laid the groundwork, 2024 marked a decisive turn. Multiple events converged to accelerate AI adoption in pharmaceutical development and in topical drug delivery specifically.
On the regulatory front, two major frameworks arrived in rapid succession. The EU AI Act — the first comprehensive AI legislation in history — came into effect on August 1, 2024, establishing clear rules for high-risk AI applications including those in pharmaceutical development. China's NMPA published a framework outlining 15 specific AI application possibilities in drug regulation, including decision assistance and approval procedures. That regulatory clarity mattered enormously for a high-growth region where pharmaceutical R&D investment was already expanding.
Industry consolidation reflected growing confidence in the technology. Recursion Pharmaceuticals and Exscientia merged in a roughly $688 million deal, combining phenomics-based high-throughput screening with AI-driven molecular design to create an end-to-end discovery platform with direct dermatological relevance. In India, Aurigene Pharmaceutical Services introduced an AI and machine learning-enabled drug discovery platform delivering a 35% reduction in development times — demonstrating AI's scalability beyond traditional pharmaceutical hubs. Investment flows confirmed the trend: AI-enabled drug discovery startups raised $3.3 billion in VC funding in 2024. L'Oréal acquired a 10% stake in Galderma, later increasing it to 20% in 2025–2026, alongside a scientific R&D collaboration in dermatology — a signal that the boundary between pharmaceutical and cosmeceutical AI applications in skin science was becoming more porous.
2025: Platforms, Partnerships, and Clinical Proof Points
By 2025, the conversation shifted from whether AI could contribute to topical drug delivery to demonstrating measurable outcomes. Eli Lilly introduced its TuneLab AI platform, making machine learning models for drug research and formulation improvement more widely accessible. The platform's significance lay not only in its technical capabilities but in its accessibility: companies seeking to optimize physicochemical characteristics for topical and transdermal delivery gained a concrete tool rather than a research prototype.
Clinical results provided the most persuasive argument. Takeda Pharmaceutical reported that more than half of patients achieved clear or almost clear skin within 16 weeks with its AI-developed psoriasis medication. In a therapeutic area where topical treatments play a central role in managing chronic conditions, that result carried significant weight.
The investment environment reached a new threshold. AI-focused businesses accounted for 61% of worldwide VC investment, representing $258.7 billion from a total of $427.1 billion — more than tripling their share from 2022. AI infrastructure companies alone drew $109.3 billion in the year. The computational resources needed to run molecular simulations, train permeability prediction models, and support clinical trial design were no longer a limiting factor for well-funded organizations.
2025–2026: Joint Regulatory Guidance and Infrastructure at Scale
The convergence of regulatory harmonization and infrastructure investment in 2025 and 2026 created conditions for more rapid, more confident AI deployment across the topical drug delivery value chain. The U.S. FDA and EMA released joint guidelines for AI use in pharmaceutical development, emphasizing data quality, model transparency, and lifecycle monitoring. Joint guidance from two major regulatory authorities reduced a persistent friction point for global developers: navigating divergent requirements simultaneously. For formulation modeling and skin permeability prediction specifically, the guidelines expanded the legitimate space for AI application across both regions.
On the infrastructure side, NVIDIA and Eli Lilly collaborated to establish AI co-innovation centers with up to $1 billion invested over five years. The partnership was designed to provide advanced computational infrastructure for AI-based formulation modeling, drug-skin interaction simulation, and digital twin creation for topical delivery devices — signaling that pharmaceutical-grade AI infrastructure had become a strategic priority rather than a supplementary capability.
The Market Today: Segments, Regions, and Investment Dynamics
The AI impact on topical drug delivery, as characterized in BCC Research's 2026 Pulse Report, spans nine distinct segments and five major regions, reflecting how thoroughly AI has permeated the value chain.
AI is active at every pipeline stage. In drug discovery and molecule design, platforms analyze large chemical and biological datasets to identify candidates with optimal lipophilicity and molecular size for skin penetration. In formulation development, Bayesian optimization has demonstrated its value concretely: ibuprofen topical gel work achieved a permeation flux of 14.15 ± 0.77 μg/cm²/h compared with 11.28 ± 0.35 μg/cm²/h using conventional methods. Deep learning models predict transdermal permeability coefficients with 93% accuracy, supplementing or replacing extensive laboratory testing. In the cosmetics and cosmeceutical segment, L'Oréal's use of the NVIDIA ALCHEMI platform increased formulation discovery speed by up to 100-fold compared with conventional techniques.
Regionally, North America leads in AI integration, anchored by robust academic institutions, sophisticated pharmaceutical R&D ecosystems, and VC activity concentrated in California and Massachusetts. Europe is advancing through regulatory alignment and cooperative research, with Basel emerging as a hub for drug delivery and drug-device businesses. Asia-Pacific is the highest-growth region, where AI adoption has produced documented reductions in development time of 20% to 50% and R&D efficiency increases of 30% to 40%. The UAE stands out within the Middle East for advanced AI usage in healthcare, with dermatology a major focus area. Australia is incorporating AI into clinical processes including dermatology screening and decision-support tools, supported by government-backed digital health projects.
Structural constraints remain. Dedicated VC funding for drug delivery specifically represents only about 0.8% of all AI-biopharma deals. Implementation costs ranging from $25,000 to $100,000 per AI use case create barriers for smaller organizations. Divergent regulatory frameworks across the U.S., EU, and Asia continue to create compliance complexity for global developers.
Where the Market Goes Next
The near-term trajectory is shaped by maturing technology, growing clinical evidence, and sustained infrastructure investment.
Generative AI and deep learning for molecular design are already producing candidates that have advanced into clinical trials. Platforms such as Insilico Medicine's Pharma.AI optimize lipophilicity, molecular size, and biological activity for dermatological targets. As models improve and training datasets expand, the speed advantage over conventional discovery will compound.
AI-optimized nanocarriers and smart transdermal delivery systems represent a particularly significant frontier. AI algorithms are being applied to design lipid-based delivery systems, stimuli-responsive platforms, and smart transdermal patches with controlled release. Integration with wearable skin sensors enables real-time treatment monitoring and dynamic dosing adjustment — a convergence of drug delivery and digital health that conventional development processes could not have produced at comparable speed or precision.
High-performance computing infrastructure, including Japan's Tokyo-1 AI supercomputer developed with Mitsui & Co. and NVIDIA, is enabling molecular simulations and digital twin modeling for drug delivery devices at previously unavailable scale. Japanese pharmaceutical companies including Astellas Pharma, Daiichi Sankyo, and Ono Pharmaceutical are among those engaging with this infrastructure for formulation AI model development.
Global pharmaceutical investment in AI is predicted to increase significantly between 2025 and 2030, driven by the need to shorten development times, increase success rates, and streamline formulation procedures — pressures that show no sign of diminishing given an average drug development cost of $879.3 million and industry-wide R&D expenditure in the tens of billions annually.
Conclusion
The arc from the FDA's first review of AI-assisted medication applications in 2016 to NVIDIA and Eli Lilly's billion-dollar co-innovation commitment in 2026 is a story of progressive legitimization. AI tools moved from peripheral experiments to central components of pharmaceutical strategy because they delivered measurable results: faster formulation discovery, more accurate permeability prediction, better clinical outcomes in dermatological conditions. Regulatory frameworks in the U.S., EU, and Asia caught up, reducing uncertainty and enabling broader deployment.
Topical drug delivery is, in many respects, an ideal domain for AI application. The skin barrier is a well-defined system with a rich experimental literature, and the challenge of optimizing molecules and formulations for permeation is precisely the kind of high-dimensional problem that machine learning handles well. As computing power increases, models improve, and datasets expand, the advantages AI brings to this segment will only compound.
